{"id":"cangrelor","rwe":[{"pmid":"41877283","year":"2026","title":"Factors influencing the interpretation of meta-analytic findings in cangrelor research.","finding":"","journal":"Critical care (London, England)","studyType":"Clinical Study"},{"pmid":"41820070","year":"2026","title":"The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial.","finding":"","journal":"Cardiovascular revascularization medicine : including molecular interventions","studyType":"Clinical Study"},{"pmid":"41819190","year":"2026","title":"Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 survey.","finding":"","journal":"International journal of cardiology","studyType":"Clinical Study"},{"pmid":"41810258","year":"2026","title":"Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease.","finding":"","journal":"HCA healthcare journal of medicine","studyType":"Clinical Study"},{"pmid":"41806688","year":"2026","title":"Hippocampal GPR17 is involved in chronic restraint stress-induced depressive-like behaviors by regulating neuroinflammation and glutamatergic activity in mice.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"}],"_fda":{"id":"8c5e6180-c346-48e7-818d-471089de4ee7","set_id":"88b434fa-8891-4fd5-9d86-7ea64667c08f","openfda":{"nui":["N0000182142","N0000008832","N0000182143"],"unii":["6AQ1Y404U7"],"route":["INTRAVENOUS"],"rxcui":["1656056","1656061"],"spl_id":["8c5e6180-c346-48e7-818d-471089de4ee7"],"brand_name":["KENGREAL"],"spl_set_id":["88b434fa-8891-4fd5-9d86-7ea64667c08f"],"package_ndc":["10122-620-01","10122-620-10"],"product_ndc":["10122-620"],"generic_name":["CANGRELOR"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Decreased Platelet Aggregation [PE]"],"substance_name":["CANGRELOR"],"pharm_class_epc":["P2Y12 Platelet Inhibitor [EPC]"],"pharm_class_moa":["P2Y12 Receptor Antagonists [MoA]"],"manufacturer_name":["Chiesi USA, Inc."],"application_number":["NDA204958"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on cangrelor use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant women and fetus ( see Clinical Considerations ). In animal reproduction studies, continuous infusion of cangrelor in pregnant rats and rabbits throughout organogenesis at dose approximately 2-times the maximum recommended human dose (MRHD) did not result in fetal malformations ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of cangrelor on the fetus. Labor or delivery Cangrelor use during labor and delivery may increase the risk for maternal bleeding and hemorrhage. Performance of neuraxial blockade procedures is not advised during cangrelor use due to potential risk of spinal hematoma. When possible, discontinue cangrelor 1 hour prior to labor, delivery, or neuraxial blockade [see Clinical Pharmacology ( 12.2 )]. Data Animal Data A prenatal and postnatal development study in female rats demonstrated a slight increase in the incidence of maternal mortality in dams treated at doses up to 30 mcg/kg/min (approximately 7.5 times the MRHD) cangrelor continuous infusion from Day 6 of gestation up to Day 23 post-partum. Pregnancy rates, gestation index, length of gestation, numbers of live, dead and malformed pups, sex ratio, live birth index, and lactation of the maternal animals were unaffected. Cangrelor administered at dose levels of ≥ 3 mcg/kg/min in pregnant rats from Day 6 to 17 post-coitum resulted in dose-related fetal growth retardation characterized by increased incidences of incomplete ossification and unossified hind limb metatarsals. An embryo-fetal development study in rabbits administered 4, 12, or 36 mcg/kg/min cangrelor continuous IV infusion from Day 6 to Day 19 post-coitum resulted in increased incidences of abortion and intrauterine losses at ≥12 mcg/kg/min (3 times the MRHD). Fetal growth retardation occurred at 36 mcg/kg/min (9 times the MRHD) and was characterized by decreased fetal weights, slight reduction in ossification, and a slight increase in skeletal variants. Cangrelor did not produce malformations in either the rat or rabbit embryo-fetal development studies and is not considered to be a teratogen."],"overdosage":["10 OVERDOSAGE There is no specific treatment to reverse the antiplatelet effect of KENGREAL but the effect is gone within one hour after the drug is discontinued. In clinical trials, 36 patients received an overdose of KENGREAL, ranging from 36 to 300 mcg/kg (bolus dose) or 4.8 to 13.7 mcg/kg/min (infusion dose). The maximum overdose received was 10 times the PCI bolus dose or 3.5 times the PCI infusion dose in 4 patients. No clinical sequela were noted as a result of overdose following completion of KENGREAL therapy."],"description":["11 DESCRIPTION KENGREAL is a direct-acting P2Y 12 platelet receptor inhibitor that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation. The chemical structure is similar to adenosine triphosphate (ATP). The chemical name of KENGREAL is tetrasodium salt of N6-[2-(methylthio)ethyl]-2-[(3,3,3,-trifluoropropyl)-5’-adenylic acid, monanhydride with (dichloromethylene) bisphosphonic acid. The empirical formula of KENGREAL is C 17 H 21 N 5 C l2 F 3 Na 4 O 12 P 3 S 2 and the molecular weight is 864.3 g/mol. The chemical structure is represented below: Cangrelor for Injection is a sterile white to off-white lyophilized powder for IV infusion. In addition to the active ingredient, cangrelor, each single use vial contains mannitol (158 mg), sorbitol (52 mg), and sodium hydroxide to adjust the pH. chemical structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING KENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials. NDC # 10122-620-01: 10 mL vial containing 50 mg cangrelor NDC # 10122-620-10: 10 count of 10 mL vials containing 50 mg cangrelor Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREAL ® is a registered trademeark of Chiesi Farmaceutici S.p.A. Distributed by: Chiesi USA, Inc. Cary, NC 27518 US-126-3-SPL"],"geriatric_use":["8.5 Geriatric Use In CHAMPION PHOENIX, 18% of patients were ≥75 years. No overall differences in safety or effectiveness were observed between these patients and those patients <75 years [see Clinical Studies ( 14.1 )] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20251021","clinical_studies":["14 CLINICAL STUDIES 14.1 CHAMPION PHOENIX Trial The CHAMPION PHOENIX trial was intended to test whether faster platelet inhibition with cangrelor at the time of PCI would reduce the rate of periprocedural thrombotic events compared to a drug with a slower antiplatelet effect, clopidogrel, given at about the time of PCI. It was a randomized, double-blind study in which patients with coronary artery disease (stable angina, UA/NSTEMI, STEMI) requiring PCI and receiving standard therapy including aspirin and heparin or bivalirudin were randomized 1:1 to KENGREAL (n=5472) or to clopidogrel 300 or 600 mg (n=5470). Patients who had already taken an oral P2Y 12 platelet inhibitor were not eligible to enroll. Patients administered glycoprotein IIb/IIIa inhibitors (GPI) or for whom GPI use was planned were also not eligible to enroll. PHOENIX was thus a study of people undergoing PCI who had not been previously treated with anti-platelet therapy other than aspirin. The primary outcome measure was the first occurrence of any one of the composite endpoint of all-cause mortality, myocardial infarction (MI), ischemia-driven revascularization (IDR), and stent thrombosis (ST) within 48 hours after randomization. KENGREAL was administered as 30 mcg/kg bolus followed by 4 mcg/kg/min infusion for 2 to 4 hours. Clopidogrel 600 mg was administered immediately at the end of the KENGREAL infusion in patients randomized to KENGREAL. Clopidogrel 300 mg or 600 mg was administered shortly before PCI or shortly afterward, in patients randomized to clopidogrel. KENGREAL significantly reduced the occurrence of primary composite endpoint events compared to clopidogrel (relative risk reduction [RRR] 22%). Most of the effect was a reduction in post-procedural MIs detected solely by elevations in CK-MB (type 4a MI). KENGREAL did not reduce the risk of death. Table 2 shows the study results for the primary composite endpoint and the contribution of each component to the primary endpoint. Table 2: Primary Endpoint and Its Component Events at 48 Hours in CHAMPION PHOENIX (mITT population a ) KENGREAL (N=5470) n (%) Clopidogrel (N=5469) n (%) KENGREAL vs. clopidogrel OR (95% CI) p-value Primary Endpoint Death/MI/IDR/ST 257 (4.7) 322 (5.9) 0.78 (0.66,0.93) b 0.005 Death 18 (0.3) 18 (0.3) MI 202 (3.7) 254 (4.6) IDR 10 (0.2) 14 (0.3) ST 27 (0.5) 36 (0.7) Note: if a subject had more than one event at 48 hours, then worst outcome counted (death >MI >IDR >ST) a The mITT population is all randomized subjects who received at least one dose of study drug and underwent the index PCI procedure b Based on logistic model adjusted for loading dose and baseline patient status for primary endpoint A supplementary analysis was also performed omitting two subcomponent events of the primary endpoint that were of lesser clinical significance: intraprocedural stent thrombosis (defined as a new or increasing thrombus within or adjacent to a deployed stent occurring during the index PCI procedure), and myocardial infarction with less than a 10-fold increase in CK-MB, or with less than a 5-fold increase in CK-MB in the presence of new Q waves or new left bundle branch block (LBBB). These results are shown in Table 3. Table 3: Supplementary Endpoint and Its Component Events at 48 Hours in CHAMPION PHOENIX (mITT population) n (%) KENGREAL ( N=5470 ) Clopidogrel ( N=5469 ) KENGREAL vs. clopidogrel OR (95% CI) Supplementary Endpoint Death/SCAI-MI/IDR/ARC-ST 79 (1.4) 114 (2.1) 0.69 (0.52,0.92) Death 18 (0.3) 18 (0.3) SCAI-MI a 48 (0.9) 80 (1.5) IDR 13 (0.2) 16 (0.3) ARC-ST b 0 (0.0) 0 (0.0) Note: if a subject had more than one event at 48 hours, then worst outcome counted (death >SCAI-MI >IDR >ARC-ST) a SCAI MI: CK-MB ≥10X ULN, or CK-MB ≥5X ULN with new Q waves or new LBBB b ARC-ST defined according to the ARC definition [Cutlip et al. 2007] The effect of KENGREAL appeared to be consistent in a variety of pre-specified and other clinically important subgroups (see Figure 4). Figure 4: CHAMPION PHOENIX Study: Primary Efficacy Endpoint by Subgroup ( mITT Population a ) a The mITT population is all randomized subjects who received at least one dose of study drug and underwent the index PCI procedure. Note: The figure above presents effects in various subgroups most of which are baseline characteristics and most of which were pre-specified (patient presentation and weight were not pre-specified subgroups). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. Figure 4: CHAMPION PHOENIX Study: Primary Efficacy Endpoint by Subgroup (mITT Populationa) 14.2 CHAMPION PCI and PLATFORM Trials Two additional concurrent clinical trials of the effect of KENGREAL in patients undergoing percutaneous coronary intervention, CHAMPION PCI and CHAMPION PLATFORM were conducted and terminated early for futility. They were completed prior to the design and conduct of CHAMPION PHOENIX. The comparative characteristics and outcomes of each trial are shown in Table 4. Table 4: Summary of the CHAMPION Trials PCI PLATFORM PHOENIX Subjects Randomized (% of planned enrollment) 8,846 (99%) 5,346 (84%) 11,145 (100%) Primary Endpoint at 48 hours Death, MI, or IDR Death, MI, or IDR Death, MI, IDR, or ST Outcome of primary analysis, OR (95% CI) 1.05 (0.88, 1.24) 0.87 (0.71, 1.07) 0.78 (0.66, 0.93) Clopidogrel dose and time in clopidogrel arm 600 mg immediately before PCI 600 mg immediately after PCI 300 or 600 mg shortly before or shortly after PCI Population enrolled (%) Stable angina 15% 5% 58% UA/NSTEMI 74% 95% 26% STEMI 11% Excluded 16%"],"pharmacodynamics":["12.2 Pharmacodynamics Cangrelor inhibits activation and aggregation of platelets. After administration of a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min IV infusion, platelet inhibition occurs within 2 minutes. Figure 2 shows the effect on platelet activity, and its relation to cangrelor plasma concentration, of administering a 30 mcg/kg IV bolus, followed by a 1-hour 4 mcg/kg/min IV infusion, of cangrelor. The anti-platelet effect is maintained for the duration of the infusion. After discontinuation of the infusion, the anti-platelet effect decreases rapidly and platelet function returns to normal within 1 hour. Figure 2 : Cangrelor PD Characteristics Figure 2: Cangrelor PD Characteristics"],"pharmacokinetics":["12.3 Pharmacokinetics KENGREAL administered intravenously has linear pharmacokinetics in both healthy volunteers and patients. KENGREAL is rapidly distributed and metabolized, reaching C max within 2 minutes after administration of an intravenous bolus followed by infusion. Distribution In a study in healthy volunteers, KENGREAL administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L. Plasma protein binding of KENGREAL is about 97-98%. Metabolism KENGREAL is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. KENGREAL’s metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes. Elimination Following IV administration of [ 3 H] KENGREAL 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion. The average elimination half-life of KENGREAL is about 3-6 minutes. Specific Populations KENGREAL pharmacokinetics are not affected by sex, age, renal status or hepatic function. No dose adjustment is needed for these factors [see Use in Specific Populations ( 8 )] . Weight Although weight was a significant covariate for PK with higher clearance in heavier patients, the impact of weight on drug exposure is accounted by the use of weight-based dosing. Drug-Drug Interactions Co-administration of cangrelor with unfractionated heparin, aspirin, and nitroglycerin was formally studied in healthy subjects, with no evidence of an effect on the PK/PD of cangrelor. In clinical trials cangrelor has been co-administered with bivalirudin, low molecular weight heparin, clopidogrel, prasugrel, and ticagrelor without clinically detectable interactions. The expected antiplatelet effect of a 600 mg loading dose of clopidogrel or a 60 mg loading dose of prasugrel was blocked when clopidogrel or prasugrel was administered during a cangrelor infusion [see Drug Interactions ( 7.1 )] . In contrast, the antiplatelet effect of a 180 mg ticagrelor loading dose was not altered significantly when ticagrelor was administered during cangrelor infusion [see Drug Interactions ( 7.1 )] . Figure 3: Inhibition (Mean) of 20 µM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Cangrelor 30 mcg/kg Bolus and 120-minute 4 mcg/kg Infusion with Transition to Other Oral P2Y 12 Platelet Inhibitors. As shown in Figure 3, discontinuation of cangrelor infusion, followed by administration of the irreversible P2Y 12 platelet inhibitors clopidogrel or prasugrel led to a 1-hour decrease in IPA followed by an increase in inhibition of platelet aggregation beginning at about one hour. This time course of platelet inhibition reflects the pharmacokinetics of cangrelor (offset) followed by the absorption and metabolism of clopidogrel and prasugrel to active metabolites (onset). Administration of ticagrelor, a reversible P2Y 12 platelet inhibitor, during the cangrelor infusion led to minimal decrease in platelet inhibition for approximately 0.5 hour following discontinuation of the cangrelor infusion. Administering ticagrelor during cangrelor infusion does not attenuate the anti-platelet effect of ticagrelor. In vitro studies suggest that neither cangrelor nor its major metabolites inhibit the activity of the hepatic CYP isoenzymes at therapeutic concentrations. Therefore, cangrelor administration is not expected to interfere with the hepatic metabolism of other concomitantly administered therapeutic agents. Figure 3: Inhibition (Mean) of 20 µM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Cangrelor 30 mcg/kg Bolus and 120-minute 4 mcg/kg Infusion with Transition to Other Oral P2Y12 Platelet Inhibitors."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere in the labeling: Bleeding [see Warnings and Precautions ( 5.1 )] The most common adverse reaction is bleeding. ( 5.1 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of KENGREAL has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial. Bleeding There was a greater incidence of bleeding with KENGREAL than with clopidogrel. No baseline demographic factor altered the relative risk of bleeding with KENGREAL (see Table 1 and Figure 1). Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding) a CHAMPION PHOENIX KENGREAL (N=5529) Clopidogrel (N=5527) Any GUSTO bleeding, n (%) 857 (15.5) 602 (10.9) Severe/life-threatening b 11 (0.2) 6 (0.1) Moderate c 21 (0.4) 14 (0.3) Mild d 825 (14.9) 582 (10.5) Any TIMI bleeding, n (%) 45 (0.8) 17 (0.3) Major e 12 (0.2) 6 (0.1) Minor f 33 (0.6) 11 (0.2) Abbreviations: GUSTO: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; TIMI: Thrombolysis in Myocardial Infarction a Safety population is all randomized subjects who received at least one dose of study drug b intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment c requiring blood transfusion but not resulting in hemodynamic compromise d all other bleeding not included in severe or moderate e any intracranial hemorrhage, or any overt bleeding associated with a reduction in hemoglobin of ≥5 g/dL (or, when hemoglobin is not available, an absolute reduction in hematocrit ≥15%) f any overt sign of bleeding (including observation by imaging techniques) that is associated with a reduction in hemoglobin of ≥3 g/dL and <5 g/dL (or, when hemoglobin is not available, an absolute reduction in hematocrit of ≥9% and <15%) Figure 1 : Bleeding Results in the CHAMPION PHOENIX Study a (All Non-CABG related) a Safety population is all randomized subjects who received at least one dose of study drug Note: The figure above presents effects in various subgroups most of which are baseline characteristics and most of which were pre-specified (patient presentation and weight were not pre-specified subgroups). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. Drug Discontinuation In CHAMPION PHOENIX the rate of discontinuation for bleeding events was 0.3% for KENGREAL and 0.1% for clopidogrel. Discontinuation for non-bleeding adverse events was low and similar for KENGREAL (0.6%) and for clopidogrel (0.4%). Coronary artery dissection, coronary artery perforation, and dyspnea were the most frequent events leading to discontinuation in patients treated with KENGREAL. Non -Bleeding Adverse Reactions Hypersensitivity Serious cases of hypersensitivity were more frequent with KENGREAL (7/13301) than with control (2/12861). These included anaphylactic reactions, anaphylactic shock, bronchospasm, angioedema, and stridor. Decreased renal function Worsening renal function was reported in 3.2% of KENGREAL patients with severe renal impairment (creatinine clearance <30 mL/min) compared to 1.4% of clopidogrel patients with severe renal impairment. Dyspnea Dyspnea was reported more frequently in patients treated with KENGREAL (1.3%) than with control (0.4%). Figure 1: Bleeding Results in the CHAMPION PHOENIX Studya (All Non-CABG related)","6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of KENGREAL has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial. Bleeding There was a greater incidence of bleeding with KENGREAL than with clopidogrel. No baseline demographic factor altered the relative risk of bleeding with KENGREAL (see Table 1 and Figure 1). Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding) a CHAMPION PHOENIX KENGREAL (N=5529) Clopidogrel (N=5527) Any GUSTO bleeding, n (%) 857 (15.5) 602 (10.9) Severe/life-threatening b 11 (0.2) 6 (0.1) Moderate c 21 (0.4) 14 (0.3) Mild d 825 (14.9) 582 (10.5) Any TIMI bleeding, n (%) 45 (0.8) 17 (0.3) Major e 12 (0.2) 6 (0.1) Minor f 33 (0.6) 11 (0.2) Abbreviations: GUSTO: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; TIMI: Thrombolysis in Myocardial Infarction a Safety population is all randomized subjects who received at least one dose of study drug b intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment c requiring blood transfusion but not resulting in hemodynamic compromise d all other bleeding not included in severe or moderate e any intracranial hemorrhage, or any overt bleeding associated with a reduction in hemoglobin of ≥5 g/dL (or, when hemoglobin is not available, an absolute reduction in hematocrit ≥15%) f any overt sign of bleeding (including observation by imaging techniques) that is associated with a reduction in hemoglobin of ≥3 g/dL and <5 g/dL (or, when hemoglobin is not available, an absolute reduction in hematocrit of ≥9% and <15%) Figure 1 : Bleeding Results in the CHAMPION PHOENIX Study a (All Non-CABG related) a Safety population is all randomized subjects who received at least one dose of study drug Note: The figure above presents effects in various subgroups most of which are baseline characteristics and most of which were pre-specified (patient presentation and weight were not pre-specified subgroups). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. Drug Discontinuation In CHAMPION PHOENIX the rate of discontinuation for bleeding events was 0.3% for KENGREAL and 0.1% for clopidogrel. Discontinuation for non-bleeding adverse events was low and similar for KENGREAL (0.6%) and for clopidogrel (0.4%). Coronary artery dissection, coronary artery perforation, and dyspnea were the most frequent events leading to discontinuation in patients treated with KENGREAL. Non -Bleeding Adverse Reactions Hypersensitivity Serious cases of hypersensitivity were more frequent with KENGREAL (7/13301) than with control (2/12861). These included anaphylactic reactions, anaphylactic shock, bronchospasm, angioedema, and stridor. Decreased renal function Worsening renal function was reported in 3.2% of KENGREAL patients with severe renal impairment (creatinine clearance <30 mL/min) compared to 1.4% of clopidogrel patients with severe renal impairment. Dyspnea Dyspnea was reported more frequently in patients treated with KENGREAL (1.3%) than with control (0.4%). Figure 1: Bleeding Results in the CHAMPION PHOENIX Studya (All Non-CABG related)"],"contraindications":["4 CONTRAINDICATIONS Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 ) 4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . 4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product [see Adverse Reactions ( 6.1 )] .","4.1 Significant Active Bleeding KENGREAL is contraindicated in patients with significant active bleeding [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] .","4.2 Hypersensitivity KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product [see Adverse Reactions ( 6.1 )] ."],"drug_interactions":["7 DRUG INTERACTIONS Clopidogrel: Do not administer during KENGREAL infusion. ( 7.1 ) Prasugrel: Do not administer during KENGREAL infusion. ( 7.1 ) 7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].","7.1 Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]."],"mechanism_of_action":["12.1 Mechanism of Action Cangrelor is a direct P2Y 12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y 12 receptor to prevent further signaling and platelet activation."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Cangrelor is a direct P2Y 12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y 12 receptor to prevent further signaling and platelet activation. 12.2 Pharmacodynamics Cangrelor inhibits activation and aggregation of platelets. After administration of a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min IV infusion, platelet inhibition occurs within 2 minutes. Figure 2 shows the effect on platelet activity, and its relation to cangrelor plasma concentration, of administering a 30 mcg/kg IV bolus, followed by a 1-hour 4 mcg/kg/min IV infusion, of cangrelor. The anti-platelet effect is maintained for the duration of the infusion. After discontinuation of the infusion, the anti-platelet effect decreases rapidly and platelet function returns to normal within 1 hour. Figure 2 : Cangrelor PD Characteristics Figure 2: Cangrelor PD Characteristics 12.3 Pharmacokinetics KENGREAL administered intravenously has linear pharmacokinetics in both healthy volunteers and patients. KENGREAL is rapidly distributed and metabolized, reaching C max within 2 minutes after administration of an intravenous bolus followed by infusion. Distribution In a study in healthy volunteers, KENGREAL administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L. Plasma protein binding of KENGREAL is about 97-98%. Metabolism KENGREAL is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. KENGREAL’s metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes. Elimination Following IV administration of [ 3 H] KENGREAL 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion. The average elimination half-life of KENGREAL is about 3-6 minutes. Specific Populations KENGREAL pharmacokinetics are not affected by sex, age, renal status or hepatic function. No dose adjustment is needed for these factors [see Use in Specific Populations ( 8 )] . Weight Although weight was a significant covariate for PK with higher clearance in heavier patients, the impact of weight on drug exposure is accounted by the use of weight-based dosing. Drug-Drug Interactions Co-administration of cangrelor with unfractionated heparin, aspirin, and nitroglycerin was formally studied in healthy subjects, with no evidence of an effect on the PK/PD of cangrelor. In clinical trials cangrelor has been co-administered with bivalirudin, low molecular weight heparin, clopidogrel, prasugrel, and ticagrelor without clinically detectable interactions. The expected antiplatelet effect of a 600 mg loading dose of clopidogrel or a 60 mg loading dose of prasugrel was blocked when clopidogrel or prasugrel was administered during a cangrelor infusion [see Drug Interactions ( 7.1 )] . In contrast, the antiplatelet effect of a 180 mg ticagrelor loading dose was not altered significantly when ticagrelor was administered during cangrelor infusion [see Drug Interactions ( 7.1 )] . Figure 3: Inhibition (Mean) of 20 µM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Cangrelor 30 mcg/kg Bolus and 120-minute 4 mcg/kg Infusion with Transition to Other Oral P2Y 12 Platelet Inhibitors. As shown in Figure 3, discontinuation of cangrelor infusion, followed by administration of the irreversible P2Y 12 platelet inhibitors clopidogrel or prasugrel led to a 1-hour decrease in IPA followed by an increase in inhibition of platelet aggregation beginning at about one hour. This time course of platelet inhibition reflects the pharmacokinetics of cangrelor (offset) followed by the absorption and metabolism of clopidogrel and prasugrel to active metabolites (onset). Administration of ticagrelor, a reversible P2Y 12 platelet inhibitor, during the cangrelor infusion led to minimal decrease in platelet inhibition for approximately 0.5 hour following discontinuation of the cangrelor infusion. Administering ticagrelor during cangrelor infusion does not attenuate the anti-platelet effect of ticagrelor. In vitro studies suggest that neither cangrelor nor its major metabolites inhibit the activity of the hepatic CYP isoenzymes at therapeutic concentrations. Therefore, cangrelor administration is not expected to interfere with the hepatic metabolism of other concomitantly administered therapeutic agents. Figure 3: Inhibition (Mean) of 20 µM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Cangrelor 30 mcg/kg Bolus and 120-minute 4 mcg/kg Infusion with Transition to Other Oral P2Y12 Platelet Inhibitors."],"indications_and_usage":["1 INDICATIONS AND USAGE KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. KENGREAL is a P2Y 12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Bleeding: Like other drugs that inhibit platelet P2Y 12 function, KENGREAL can increase the risk of bleeding ( 5.1 ) 5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel [see Adverse Reactions ( 6.1 )] . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1). Once KENGREAL is discontinued, there is no antiplatelet effect after an hour [see Clinical Pharmacology ( 12.3 )] .","5.1 Bleeding Drugs that inhibit platelet P2Y 12 function, including KENGREAL, increase the risk of bleeding. In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel [see Adverse Reactions ( 6.1 )] . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1). Once KENGREAL is discontinued, there is no antiplatelet effect after an hour [see Clinical Pharmacology ( 12.3 )] ."],"clinical_studies_table":["
Table 2: Primary Endpoint and Its Component Events at 48 Hours in CHAMPION PHOENIX (mITT populationa)
KENGREAL (N=5470) n (%) Clopidogrel (N=5469) n (%) KENGREAL vs. clopidogrel
OR (95% CI) p-value
Primary Endpoint Death/MI/IDR/ST 257 (4.7) 322 (5.9) 0.78 (0.66,0.93) b 0.005
Death 18 (0.3) 18 (0.3)
MI 202 (3.7) 254 (4.6)
IDR 10 (0.2) 14 (0.3)
ST 27 (0.5) 36 (0.7)
","
Table 3: Supplementary Endpoint and Its Component Events at 48 Hours in CHAMPION PHOENIX (mITT population)
n (%) KENGREAL (N=5470) Clopidogrel (N=5469) KENGREAL vs. clopidogrel OR (95% CI)
Supplementary Endpoint Death/SCAI-MI/IDR/ARC-ST 79 (1.4) 114 (2.1) 0.69 (0.52,0.92)
Death 18 (0.3) 18 (0.3)
SCAI-MIa 48 (0.9) 80 (1.5)
IDR 13 (0.2) 16 (0.3)
ARC-STb 0 (0.0) 0 (0.0)
","
Table 4: Summary of the CHAMPION Trials
PCI PLATFORM PHOENIX
Subjects Randomized (% of planned enrollment) 8,846 (99%) 5,346 (84%) 11,145 (100%)
Primary Endpoint at 48 hours Death, MI, or IDR Death, MI, or IDR Death, MI, IDR, or ST
Outcome of primary analysis, OR (95% CI) 1.05 (0.88, 1.24) 0.87 (0.71, 1.07) 0.78 (0.66, 0.93)
Clopidogrel dose and time in clopidogrel arm 600 mg immediately before PCI 600 mg immediately after PCI 300 or 600 mg shortly before or shortly after PCI
Population enrolled (%) Stable angina 15% 5% 58%
UA/NSTEMI 74% 95% 26%
STEMI 11% Excluded 16%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies were conducted. Mutagenesis Cangrelor was non-mutagenic and non-clastogenic in genetic toxicology studies, including in vitro bacterial gene mutation assay, mouse lymphoma thymidine kinase assay, chromosome aberration assay in human peripheral lymphocytes, and in vivo bone marrow micronucleus assay in mice. Impairment of Fertility Cangrelor had no significant effect on male or female rats fertility treated by continuous infusion for 28 days, or on early embryonic development at steady state plasma concentration (Css) of approximately the same as that achieved in the PCI setting at the MRHD."],"adverse_reactions_table":["
Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding)a
CHAMPION PHOENIX KENGREAL (N=5529) Clopidogrel (N=5527)
Any GUSTO bleeding, n (%) 857 (15.5) 602 (10.9)
Severe/life-threatening b 11 (0.2) 6 (0.1)
Moderate c 21 (0.4) 14 (0.3)
Mild d 825 (14.9) 582 (10.5)
Any TIMI bleeding, n (%) 45 (0.8) 17 (0.3)
Major e 12 (0.2) 6 (0.1)
Minor f 33 (0.6) 11 (0.2)
","
Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding)a
CHAMPION PHOENIX KENGREAL (N=5529) Clopidogrel (N=5527)
Any GUSTO bleeding, n (%) 857 (15.5) 602 (10.9)
Severe/life-threatening b 11 (0.2) 6 (0.1)
Moderate c 21 (0.4) 14 (0.3)
Mild d 825 (14.9) 582 (10.5)
Any TIMI bleeding, n (%) 45 (0.8) 17 (0.3)
Major e 12 (0.2) 6 (0.1)
Minor f 33 (0.6) 11 (0.2)
"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION KENGREAL is intended for administration via a dedicated IV line, only after reconstitution and dilution. ( 2.3 ) Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer. ( 2.1 ) To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor. ( 2.2 ) 2.1 Recommended Dosing The recommended dosage of KENGREAL is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer. 2.2 Transitioning Patients to Oral P2Y 12 Therapy To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor, as described below: Ticagrelor: 180 mg at any time during KENGREAL infusion or immediately after discontinuation [see Clinical Pharmacology ( 12.2 )] . Prasugrel: 60 mg immediately after discontinuation of KENGREAL [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )] . Clopidogrel: 600 mg immediately after discontinuation of KENGREAL [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )] . 2.3 Preparation and Administration KENGREAL is intended for IV administration, after reconstitution and dilution. Preparation Reconstitute the vial prior to dilution in a bag. For each 50 mg/vial, reconstitute by adding 5 mL of Sterile Water for Injection. Swirl gently until all material is dissolved. Avoid vigorous mixing. Allow any foam to settle. Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colorless to pale yellow solution. Parenteral drug products should be inspected visually for particulate matter after reconstitution. Before administration, each reconstituted vial must be diluted further with Normal Saline (Sodium Chloride Injection 0.9% USP) or 5% Dextrose Injection USP. Withdraw the contents from one reconstituted vial and add to one 250 mL saline bag. Mix the bag thoroughly. This dilution will result in a concentration of 200 mcg/mL and should be sufficient for at least 2 hours of dosing. Patients 100 kg and over will require a minimum of 2 bags. Reconstituted KENGREAL should be diluted immediately. Diluted KENGREAL is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in Normal Saline at Room Temperature. Discard any unused portion of reconstituted solution remaining in the vial. Administration Administer KENGREAL via a dedicated IV line. Administer the bolus volume rapidly (<1 minute), from the diluted bag via manual IV push or pump. Ensure the bolus is completely administered before the start of PCI. Start the infusion immediately after administration of the bolus [see Dosage and Administration ( 2.1 )] .","2.1 Recommended Dosing The recommended dosage of KENGREAL is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer.","2.2 Transitioning Patients to Oral P2Y 12 Therapy To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor, as described below: Ticagrelor: 180 mg at any time during KENGREAL infusion or immediately after discontinuation [see Clinical Pharmacology ( 12.2 )] . Prasugrel: 60 mg immediately after discontinuation of KENGREAL [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )] . Clopidogrel: 600 mg immediately after discontinuation of KENGREAL [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )] .","2.3 Preparation and Administration KENGREAL is intended for IV administration, after reconstitution and dilution. Preparation Reconstitute the vial prior to dilution in a bag. For each 50 mg/vial, reconstitute by adding 5 mL of Sterile Water for Injection. Swirl gently until all material is dissolved. Avoid vigorous mixing. Allow any foam to settle. Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colorless to pale yellow solution. Parenteral drug products should be inspected visually for particulate matter after reconstitution. Before administration, each reconstituted vial must be diluted further with Normal Saline (Sodium Chloride Injection 0.9% USP) or 5% Dextrose Injection USP. Withdraw the contents from one reconstituted vial and add to one 250 mL saline bag. Mix the bag thoroughly. This dilution will result in a concentration of 200 mcg/mL and should be sufficient for at least 2 hours of dosing. Patients 100 kg and over will require a minimum of 2 bags. Reconstituted KENGREAL should be diluted immediately. Diluted KENGREAL is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in Normal Saline at Room Temperature. Discard any unused portion of reconstituted solution remaining in the vial. Administration Administer KENGREAL via a dedicated IV line. Administer the bolus volume rapidly (<1 minute), from the diluted bag via manual IV push or pump. Ensure the bolus is completely administered before the start of PCI. Start the infusion immediately after administration of the bolus [see Dosage and Administration ( 2.1 )] ."],"spl_product_data_elements":["KENGREAL cangrelor CANGRELOR CANGRELOR MANNITOL SORBITOL SODIUM HYDROXIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS For Injection: 50 mg of KENGREAL lyophilized powder in a single-use 10 mL glass vial for reconstitution. Single-use 10 mL vial containing 50 mg KENGREAL as a lyophilized powder for reconstitution ( 3.0 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on cangrelor use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant women and fetus ( see Clinical Considerations ). In animal reproduction studies, continuous infusion of cangrelor in pregnant rats and rabbits throughout organogenesis at dose approximately 2-times the maximum recommended human dose (MRHD) did not result in fetal malformations ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of cangrelor on the fetus. Labor or delivery Cangrelor use during labor and delivery may increase the risk for maternal bleeding and hemorrhage. Performance of neuraxial blockade procedures is not advised during cangrelor use due to potential risk of spinal hematoma. When possible, discontinue cangrelor 1 hour prior to labor, delivery, or neuraxial blockade [see Clinical Pharmacology ( 12.2 )]. Data Animal Data A prenatal and postnatal development study in female rats demonstrated a slight increase in the incidence of maternal mortality in dams treated at doses up to 30 mcg/kg/min (approximately 7.5 times the MRHD) cangrelor continuous infusion from Day 6 of gestation up to Day 23 post-partum. Pregnancy rates, gestation index, length of gestation, numbers of live, dead and malformed pups, sex ratio, live birth index, and lactation of the maternal animals were unaffected. Cangrelor administered at dose levels of ≥ 3 mcg/kg/min in pregnant rats from Day 6 to 17 post-coitum resulted in dose-related fetal growth retardation characterized by increased incidences of incomplete ossification and unossified hind limb metatarsals. An embryo-fetal development study in rabbits administered 4, 12, or 36 mcg/kg/min cangrelor continuous IV infusion from Day 6 to Day 19 post-coitum resulted in increased incidences of abortion and intrauterine losses at ≥12 mcg/kg/min (3 times the MRHD). Fetal growth retardation occurred at 36 mcg/kg/min (9 times the MRHD) and was characterized by decreased fetal weights, slight reduction in ossification, and a slight increase in skeletal variants. Cangrelor did not produce malformations in either the rat or rabbit embryo-fetal development studies and is not considered to be a teratogen. 8.2 Lactation Risk Summary There are no data on the presence of cangrelor in human milk or animal milk, the effects on the breastfed infant, or the effects on milk production. However, due to its short-half life, cangrelor exposure is expected to be very low in the breastfed infant. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use In CHAMPION PHOENIX, 18% of patients were ≥75 years. No overall differences in safety or effectiveness were observed between these patients and those patients <75 years [see Clinical Studies ( 14.1 )] . 8.6 Renal Impairment No dosage adjustment is required for patients with mild, moderate, or severe renal impairment [see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment KENGREAL has not been studied in patients with hepatic impairment. However, the metabolism of KENGREAL is not dependent of hepatic function, so dosage adjustment is not required for patients with hepatic impairment [see Clinical Pharmacology ( 12.3 )] ."],"package_label_principal_display_panel":["Principal Display Panel NDC 10122-620-10 Kengreal® ( cangrelor ) for injection 50 mg per vial Rx Only 10 Single Use Vials Kengreal (cangrelor) for injection 50 mg vial carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies were conducted. Mutagenesis Cangrelor was non-mutagenic and non-clastogenic in genetic toxicology studies, including in vitro bacterial gene mutation assay, mouse lymphoma thymidine kinase assay, chromosome aberration assay in human peripheral lymphocytes, and in vivo bone marrow micronucleus assay in mice. Impairment of Fertility Cangrelor had no significant effect on male or female rats fertility treated by continuous infusion for 28 days, or on early embryonic development at steady state plasma concentration (Css) of approximately the same as that achieved in the PCI setting at the MRHD."]},"tags":[{"label":"P2Y12 Platelet Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P2Y purinoceptor 12","category":"target"},{"label":"P2RY12","category":"gene"},{"label":"P2RY13","category":"gene"},{"label":"B01AC25","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Percutaneous coronary intervention","category":"indication"},{"label":"Chiesi","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"},{"label":"Purinergic Antagonists","category":"pharmacology"},{"label":"Purinergic P2 Receptor Antagonists","category":"pharmacology"},{"label":"Purinergic P2Y Receptor Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"VASCULAR STENT THROMBOSIS","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"HAEMORRHAGE","source":"FDA FAERS","actionTaken":"26 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"CARDIOGENIC SHOCK","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"GASTROINTESTINAL HAEMORRHAGE","source":"FDA FAERS","actionTaken":"14 reports"}],"commonSideEffects":[{"effect":"Bleeding","drugRate":"15.5%","severity":"serious","_validated":true},{"effect":"Dyspnea","drugRate":"1.3%","severity":"mild","_validated":true},{"effect":"Decreased renal function","drugRate":"3.2%","severity":"serious","_validated":true},{"effect":"Hypersensitivity","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Coronary artery dissection","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Coronary artery perforation","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anaphylactic reactions","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anaphylactic shock","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Bronchospasm","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Angioedema","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Stridor","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Worsening renal function","drugRate":"1.4%","severity":"mild","_validated":true}],"specialPopulations":{"Pregnancy":"There are no available data on cangrelor use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant women and fetus (see Clinical Considerations).In animal reproduction studies, continuous infusion of cangrelor in pregnant rats and rabbits throughout organogenesis at dose approximately 2-times the maximum recommended human dose (MRHD) did not result in fetal malformations (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.Clinical ConsiderationsDisease-associated maternal and/or embryo/fetal riskMyocardial infarction is medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of cangrelor on the fetus.Labor or deliveryCangrelor use during labor and delivery may increase the risk for maternal bleeding and hemorrhage. Performance of neuraxial blockade procedures is not advised during cangrelor use due to potential for increased risk of bleeding.","Geriatric use":"In CHAMPION PHOENIX, 18% of patients were >=75 years. No overall differences in safety or effectiveness were observed between these patients and those patients <75 years [see Clinical Studies 14.1 ).]","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Chiesi","patents":[{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2035","useCode":"U-2260","territory":"US","drugProduct":false,"patentNumber":"10039780","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"May 13, 2029","useCode":"U-2260","territory":"US","drugProduct":false,"patentNumber":"9925265","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Nov 10, 2030","useCode":"U-1926","territory":"US","drugProduct":false,"patentNumber":"9427448","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Mar 9, 2033","useCode":"U-2979","territory":"US","drugProduct":false,"patentNumber":"8680052","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9439921","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9700575","drugSubstance":false},{"applNo":"N204958","source":"FDA Orange Book","status":"Active","expires":"Jul 10, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9295687","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CANGRELOR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:32.411320+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:35:32.411225+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cangrelor","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:35:41.542673+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:39.938634+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:35:32.483335+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:35:31.031110+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CANGRELOR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:40.497181+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:30.226151+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:30.226184+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:30.226190+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:42.018658+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purinergic receptor P2Y12 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:41.542617+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL334966/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:41.200732+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA204958","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:30.226194+00:00"}},"allNames":"kengreal","offLabel":[],"synonyms":["canegrelor","cangrelor","cangrelor tetrasodium","kengreal","AR-C69931XX","AR-C69931MX","kengrexal","ARL69931"],"timeline":[{"date":"2015-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MEDICINES CO to Chiesi"},{"date":"2015-03-23","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2015-06-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Medicines Co)"},{"date":"2025-08-11","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Kengreal (Cangrelor) is a P2Y12 platelet inhibitor, a small molecule drug developed by Medicines Co and currently owned by Chiesi. It targets the P2Y12 purinoceptor, a receptor on platelets that plays a key role in blood clotting. Kengreal is FDA-approved for use in percutaneous coronary intervention (PCI) and works by blocking the action of adenosine diphosphate (ADP) on platelets, thereby preventing platelet activation and aggregation. As of 2023, Kengreal is still patented, but generic manufacturers are available. Key safety considerations include bleeding risks and potential interactions with other medications.","brandName":"Kengreal","ecosystem":[{"indication":"Percutaneous coronary intervention","otherDrugs":[{"name":"abciximab","slug":"abciximab","company":"Centocor Inc"},{"name":"apraclonidine","slug":"apraclonidine","company":"Alcon"},{"name":"argatroban","slug":"argatroban","company":"Pfizer"},{"name":"bivalirudin","slug":"bivalirudin","company":"Medicines Co"}],"globalPrevalence":null}],"mechanism":{"target":"P2Y purinoceptor 12","novelty":"Follow-on","targets":[{"gene":"P2RY12","source":"DrugCentral","target":"P2Y purinoceptor 12","protein":"P2Y purinoceptor 12"},{"gene":"P2RY13","source":"DrugCentral","target":"P2Y purinoceptor 13","protein":"P2Y purinoceptor 13"}],"moaClass":"P2Y12 Receptor Antagonists","modality":"Small Molecule","drugClass":"P2Y12 Platelet Inhibitor [EPC]","explanation":"Cangrelor is direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.","oneSentence":"Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation.","technicalDetail":"Kengreal selectively and reversibly inhibits the P2Y12 receptor, a G-protein coupled receptor on platelets that is activated by ADP, thereby preventing the activation of the glycoprotein IIb/IIIa complex and subsequent platelet aggregation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cangrelor","title":"Cangrelor","extract":"Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation."},"commercial":{"launchDate":"2015","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2015-06-22, MEDICINES CO)","annualRevenue":200,"revenueSource":"Verified: Chiesi AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5006","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CANGRELOR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CANGRELOR","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cangrelor","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:08:51.184842","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:44.922415+00:00","fieldsConflicting":8,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clopidogrel","drugSlug":"clopidogrel","fdaApproval":"1997-11-17","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ticlopidine","drugSlug":"ticlopidine","fdaApproval":"1991-10-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetylsalicylic acid","drugSlug":"acetylsalicylic-acid","fdaApproval":"1950-04-12","relationship":"same-class"},{"drugName":"dipyridamole","drugSlug":"dipyridamole","fdaApproval":"1961-12-06","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"epoprostenol","drugSlug":"epoprostenol","fdaApproval":"1995-09-20","patentExpiry":"Mar 15, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"iloprost","drugSlug":"iloprost","fdaApproval":"2004-12-29","patentExpiry":"Jul 18, 2044","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"abciximab","drugSlug":"abciximab","fdaApproval":"1993-12-16","relationship":"same-class"},{"drugName":"eptifibatide","drugSlug":"eptifibatide","fdaApproval":"1998-05-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tirofiban","drugSlug":"tirofiban","fdaApproval":"1998-05-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"treprostinil","drugSlug":"treprostinil","fdaApproval":"2002-05-21","patentExpiry":"Sep 5, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prasugrel","drugSlug":"prasugrel","fdaApproval":"2009-07-10","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cilostazol","drugSlug":"cilostazol","fdaApproval":"1999-01-15","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ticagrelor","drugSlug":"ticagrelor","fdaApproval":"2011-07-20","patentExpiry":"Oct 17, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vorapaxar","drugSlug":"vorapaxar","fdaApproval":"2014-05-08","patentExpiry":"Dec 23, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selexipag","drugSlug":"selexipag","fdaApproval":"2015-12-21","patentExpiry":"Oct 31, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"cangrelor","indications":{"approved":[{"name":"Percutaneous coronary intervention","source":"DrugCentral","snomedId":415070008,"regulator":"FDA","eligibility":"patients who have not been treated with P2Y12 platelet inhibitor and are not being given glycoprotein IIb/IIIa inhibitor"}],"offLabel":[],"pipeline":[]},"currentOwner":"Chiesi","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clopidogrel","brandName":"clopidogrel","genericName":"clopidogrel","approvalYear":"1997","relationship":"same-class"},{"drugId":"ticlopidine","brandName":"ticlopidine","genericName":"ticlopidine","approvalYear":"1991","relationship":"same-class"},{"drugId":"acetylsalicylic-acid","brandName":"acetylsalicylic acid","genericName":"acetylsalicylic acid","approvalYear":"1950","relationship":"same-class"},{"drugId":"dipyridamole","brandName":"dipyridamole","genericName":"dipyridamole","approvalYear":"1961","relationship":"same-class"},{"drugId":"epoprostenol","brandName":"epoprostenol","genericName":"epoprostenol","approvalYear":"1995","relationship":"same-class"},{"drugId":"iloprost","brandName":"iloprost","genericName":"iloprost","approvalYear":"2004","relationship":"same-class"},{"drugId":"abciximab","brandName":"abciximab","genericName":"abciximab","approvalYear":"1993","relationship":"same-class"},{"drugId":"eptifibatide","brandName":"eptifibatide","genericName":"eptifibatide","approvalYear":"1998","relationship":"same-class"},{"drugId":"tirofiban","brandName":"tirofiban","genericName":"tirofiban","approvalYear":"1998","relationship":"same-class"},{"drugId":"treprostinil","brandName":"treprostinil","genericName":"treprostinil","approvalYear":"2002","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04667078","phase":"PHASE3","title":"REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-03-02","conditions":["Acute Ischemia"],"enrollment":368,"completionDate":"2030-09-01"},{"nctId":"NCT04471870","phase":"","title":"ARCANGELO (itAlian pRospective Study on CANGrELOr)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2020-10-23","conditions":["Acute Coronary Syndrome"],"enrollment":1005,"completionDate":"2022-01-17"},{"nctId":"NCT05193019","phase":"","title":"Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2022-03-14","conditions":["Ischemic Heart Disease","Acute Coronary Syndrome"],"enrollment":717,"completionDate":"2026-06-01"},{"nctId":"NCT07225842","phase":"PHASE4","title":"The Bridging Antiplatelet Therapy With Cangrelor 2 Study","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-02-25","conditions":["Coronary Arterial Disease (CAD)"],"enrollment":50,"completionDate":"2027-11"},{"nctId":"NCT05611242","phase":"PHASE3","title":"Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial","status":"RECRUITING","sponsor":"Mercy Health Ohio","startDate":"2024-05-08","conditions":["Acute Ischemic Stroke"],"enrollment":404,"completionDate":"2027-05-08"},{"nctId":"NCT04790032","phase":"","title":"Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)","status":"COMPLETED","sponsor":"Federico II University","startDate":"2021-03-16","conditions":["Percutaneous Coronary Intervention"],"enrollment":150,"completionDate":"2024-07-01"},{"nctId":"NCT04076813","phase":"","title":"Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi USA, Inc.","startDate":"2019-10-16","conditions":["Myocardial Infarction"],"enrollment":5050,"completionDate":"2025-06-30"},{"nctId":"NCT02733341","phase":"PHASE4","title":"The Effect of IV Cangrelor and Oral Ticagrelor Study","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2016-07-21","conditions":["Acute Coronary Syndrome (ACS)","High On-treatment Platelet Reactivity (HTPR)","Microvascular Obstruction (MVO)","ST-segment Elevation Myocardial Infarction (STEMI)","Thrombolysis in Myocardial Infarction (TIMI)","Unstable Angina (UA)"],"enrollment":100,"completionDate":"2018-10-01"},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":["Acute Myocardial Infarction","Cardiogenic Shock"],"enrollment":605,"completionDate":"2025-04-01"},{"nctId":"NCT06089577","phase":"PHASE4","title":"Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention","status":"RECRUITING","sponsor":"Federico II University","startDate":"2023-11-01","conditions":["Coronary Artery Disease"],"enrollment":80,"completionDate":"2026-10"},{"nctId":"NCT06792643","phase":"PHASE2","title":"Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-04-01","conditions":["Cardiogenic Shock","Extracorporeal Membrane Oxygenation Complication","Platelet Dysfunction"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT04668144","phase":"PHASE4","title":"Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-18","conditions":["Coronary Artery Disease","Acute Coronary Syndrome"],"enrollment":359,"completionDate":"2023-05-11"},{"nctId":"NCT03048019","phase":"","title":"Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2017-08-23","conditions":["Non-ST Elevation Myocardial Infarction (NSTEMI)"],"enrollment":10,"completionDate":"2019-06-27"},{"nctId":"NCT04927949","phase":"PHASE4","title":"Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-06-08","conditions":["ST-elevation Myocardial Infarction"],"enrollment":128,"completionDate":"2023-03-31"},{"nctId":"NCT04634162","phase":"PHASE4","title":"PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-09","conditions":["Coronary Artery Disease"],"enrollment":22,"completionDate":"2021-11-30"},{"nctId":"NCT02765633","phase":"PHASE1","title":"Cangrelor Neonatal PK/PD and Safety Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-01-03","conditions":["Partial Obstruction of Systemic to Pulmonary Artery Shunt","Complete Obstruction of Systemic to Pulmonary Artery Shunt"],"enrollment":22,"completionDate":"2019-12-23"},{"nctId":"NCT03445546","phase":"","title":"Platelet Function in Resuscitated Patients-2","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2016-05-01","conditions":["Acute Myocardial Infarction","Cardiac Arrest"],"enrollment":25,"completionDate":"2018-05-15"},{"nctId":"NCT05505591","phase":"","title":"Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry","status":"UNKNOWN","sponsor":"Universita degli Studi di Genova","startDate":"2022-06-06","conditions":["Bleeding","Coronary Artery Disease","Myocardial Infarction"],"enrollment":900,"completionDate":"2022-10-31"},{"nctId":"NCT04251039","phase":"","title":"in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study\"","status":"UNKNOWN","sponsor":"Fondazione GISE Onlus","startDate":"2022-12","conditions":["Coronary Disease"],"enrollment":550,"completionDate":"2023-12"},{"nctId":"NCT04611607","phase":"","title":"Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock","status":"COMPLETED","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2021-05-04","conditions":["Acute Myocardial Infarction"],"enrollment":303,"completionDate":"2022-06-07"},{"nctId":"NCT03102723","phase":"PHASE2","title":"Platelet Inhibition to Target Reperfusion Injury","status":"UNKNOWN","sponsor":"National Heart Centre Singapore","startDate":"2017-10-01","conditions":["STEMI"],"enrollment":228,"completionDate":"2022-12"},{"nctId":"NCT04005729","phase":"PHASE4","title":"Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2019-07-01","conditions":["Out-Of-Hospital Cardiac Arrest","Acute Coronary Syndrome"],"enrollment":30,"completionDate":"2021-11-27"},{"nctId":"NCT04668495","phase":"","title":"Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-01-28","conditions":["Coronary Artery Disease"],"enrollment":17,"completionDate":"2021-07-20"},{"nctId":"NCT03247738","phase":"PHASE4","title":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-11-20","conditions":["ST Segment Elevation Myocardial Infarction","Percutaneous Coronary Intervention"],"enrollment":50,"completionDate":"2018-12-13"},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":["Covid19"],"enrollment":1707,"completionDate":"2020-06-30"},{"nctId":"NCT04138641","phase":"","title":"Dutch Cangrelor Registry","status":"COMPLETED","sponsor":"Isala","startDate":"2019-12-17","conditions":["STEMI - ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation MI","Coronary Artery Disease"],"enrollment":250,"completionDate":"2020-07-24"},{"nctId":"NCT03043274","phase":"PHASE4","title":"Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size","status":"TERMINATED","sponsor":"Khaled Ziada, MD","startDate":"2017-01","conditions":["STEMI - ST Elevation Myocardial Infarction"],"enrollment":23,"completionDate":"2019-05"},{"nctId":"NCT01979445","phase":"PHASE2","title":"Cangrelor to Clopidogrel or Prasugrel Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-12-02","conditions":["Coronary Artery Disease (CAD)"],"enrollment":15,"completionDate":"2014-01-20"},{"nctId":"NCT02978040","phase":"PHASE4","title":"Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-07-04","conditions":["Coronary Artery Disease","STEMI - ST Elevation Myocardial Infarction"],"enrollment":122,"completionDate":"2019-12-27"},{"nctId":"NCT03862651","phase":"PHASE2","title":"Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2019-06-01","conditions":["Platelet Aggregation Inhibitors"],"enrollment":140,"completionDate":"2021-01-01"},{"nctId":"NCT03182855","phase":"PHASE4","title":"Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2018-09-01","conditions":["Acute Coronary Syndrome","Myocardial Infarction","STEMI - ST Elevation Myocardial Infarction"],"enrollment":80,"completionDate":"2019-08-01"},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":["Stable Angina"],"enrollment":36,"completionDate":"2009-06"},{"nctId":"NCT02943369","phase":"PHASE4","title":"Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2017-07-28","conditions":["STEMI"],"enrollment":30,"completionDate":"2017-12-26"},{"nctId":"NCT03273075","phase":"PHASE4","title":"Add-on Cangrelor in STEMI-triggered Cardiac Arrest","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2017-09","conditions":["Cardiopulmonary Arrest With Successful Resuscitation","ACS - Acute Coronary Syndrome","Hypothermia, Induced"],"enrollment":60,"completionDate":"2021-12"},{"nctId":"NCT02081443","phase":"NA","title":"In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-04","conditions":["Coronary Artery Disease"],"enrollment":60,"completionDate":"2015-10"},{"nctId":"NCT01852019","phase":"PHASE2","title":"Cangrelor Prasugrel Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-06","conditions":["Coronary Artery Disease"],"enrollment":12,"completionDate":"2013-07"},{"nctId":"NCT01766466","phase":"PHASE2","title":"Cangrelor Ticagrelor Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-01","conditions":["Coronary Artery Disease"],"enrollment":12,"completionDate":"2013-02"},{"nctId":"NCT00305162","phase":"PHASE3","title":"A Clinical Trial to Demonstrate the Efficacy of Cangrelor","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2006-04","conditions":["Myocardial Infarction (MI)","Acute Coronary Syndromes (ACS)"],"enrollment":8882,"completionDate":"2010-06"},{"nctId":"NCT00385138","phase":"PHASE3","title":"Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2006-09","conditions":["Atherosclerosis","Acute Coronary Syndrome (ACS)"],"enrollment":5364,"completionDate":"2010-06"},{"nctId":"NCT00767507","phase":"PHASE2","title":"Maintenance of Platelet Inhibition With Cangrelor","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-10","conditions":["Acute Coronary Syndrome (ACS)"],"enrollment":221,"completionDate":"2011-07"},{"nctId":"NCT01156571","phase":"PHASE3","title":"A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-09","conditions":["Atherosclerosis","Percutaneous Coronary Intervention","Acute Coronary Syndrome"],"enrollment":11145,"completionDate":"2012-12"},{"nctId":"NCT00699504","phase":"PHASE1","title":"Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-06","conditions":["Healthy"],"enrollment":67,"completionDate":"2008-11"},{"nctId":"NCT00102674","phase":"PHASE1","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2005-03","conditions":["Healthy"],"enrollment":40,"completionDate":"2005-05"}],"_emaApprovals":[{"date":"2015-03-23","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"KENGREAL"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000191733","MMSL":"234577","NDDF":"016203","UNII":"6AQ1Y404U7","VUID":"4034569","CHEBI":"CHEBI:90841","VANDF":"4034569","INN_ID":"7883","RXNORM":"1656051","UMLSCUI":"C1121991","chemblId":"CHEMBL334966","ChEMBL_ID":"CHEMBL334966","KEGG_DRUG":"D03359","DRUGBANK_ID":"DB06441","PUBCHEM_CID":"9854012","SNOMEDCT_US":"1217149008","IUPHAR_LIGAND_ID":"1776","SECONDARY_CAS_RN":"163706-36-3","MESH_SUPPLEMENTAL_RECORD_UI":"C117446"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Medicines Co","relationship":"Original Developer"},{"period":"present","companyName":"Chiesi","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.14 hours","clearance":"9.06 mL/min/kg","fractionUnbound":"0.02%","volumeOfDistribution":"0.035 L/kg"},"publicationCount":728,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-04-08 13:59:25.017544+00","atcClassification":{"source":"DrugCentral","atcCode":"B01AC25","allCodes":["B01AC25"]},"biosimilarFilings":[],"originalDeveloper":"Medicines Co","recentPublications":[{"date":"2026 Mar 24","pmid":"41877283","title":"Factors influencing the interpretation of meta-analytic findings in cangrelor research.","journal":"Critical care (London, England)"},{"date":"2026 Mar 4","pmid":"41820070","title":"The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial.","journal":"Cardiovascular revascularization medicine : including molecular interventions"},{"date":"2026 Mar 10","pmid":"41819190","title":"Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 survey.","journal":"International journal of cardiology"},{"date":"2026","pmid":"41810258","title":"Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease.","journal":"HCA healthcare journal of medicine"},{"date":"2026 May 1","pmid":"41806688","title":"Hippocampal GPR17 is involved in chronic restraint stress-induced depressive-like behaviors by regulating neuroinflammation and glutamatergic activity in mice.","journal":"International immunopharmacology"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Gland"],"status":"approved","companyName":"Chiesi","companyId":"chiesi","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-23T00:00:00.000Z","mah":"CHIESI","brand_name_local":null,"application_number":"NDA204958"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-11T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA213551"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:44.922415+00:00","fieldsConflicting":8,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}